GlassScriptPhysician profile
Haley C Overstreet
NPI 1700107323
$4,680.04
in general payments reported to CMS, 2019-2025
21 companies · $873 in 2025
The $873 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $204 · 2021: $973 · 2022: $1,035 · 2023: $726 · 2024: $663 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,229 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,228.87 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,272.75 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $988.70 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $663.51 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $319.93 | 2024-2025 | |
| Amgen INC. | $265.16 | 2022-2025 | Tezspire |
| Genzyme Corporation | $213.86 | 2019-2024 | |
| Kaleo, INC. | $202.09 | 2021-2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $160.47 | 2025 | Neffy |
| Inspire Medical Systems, INC. | $94.17 | 2025 | Inspire |
| Abbvie INC. | $72.23 | 2022-2023 | |
| Genentech USA, INC. | $70.31 | 2022-2025 | Xolair |
| Phadia US INC. | $64.45 | 2022-2024 | Immunocap |
| Optinose US, INC. | $55.13 | 2025 | |
| Aerin Medical INC. | $39.44 | 2022 | |
| Acclarent, INC | $38.62 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $38.00 | 2019 | |
| Kedrion Biopharma, INC. | $37.43 | 2025 | Koate, Kedrab, Gammaked |
| Neurent Medical Limited | $26.15 | 2024 | Neuromark Device, Neuromark Radiofrequency Console |
| Takeda Pharmaceuticals U.S.A., INC. | $25.05 | 2024 | Cuvitru |
| Covis Pharma Gmbh | $17.09 | 2022 | |
| Alk-Abello, INC | $15.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Overstreet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.